2.067  -0.043 (-2.04%)		12-15 15:59
Open: 2.11 High: 2.23 Volume: 59,344		Pre. Close: 2.11 Low: 2.02 Market Cap: 30(M)

Short term
Mid term
Targets	6-month :	3.11	1-year :	3.57
Resists	First :	2.66	Second :	3.05
Pivot price	2.41
Supports	First :	2.01	Second :	1.68
MAs	MA(5) :	2.17	MA(20) :	2.5
	MA(100) :	2.84	MA(250) :	0
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	11.5	D(3) :	16
RSI	RSI(14): 29.1
52-week	High :	5.48	Low :	0.4

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ABVC ] has closed above bottom band by 9.7%. Bollinger Bands are 33.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.23 - 2.25	2.25 - 2.26
Low:	1.99 - 2.01	2.01 - 2.02
Close:	2.05 - 2.07	2.07 - 2.09

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

Tue, 02 Dec 2025
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States - Yahoo Finance

Wed, 26 Nov 2025
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030 - Yahoo Finance

Tue, 18 Nov 2025
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million - Yahoo Finance

Mon, 03 Nov 2025
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 - Yahoo Finance

Mon, 03 Nov 2025
ABVC BIOPHARMA, INC. SEC 10-Q Report - TradingView — Track All Markets

Wed, 08 Oct 2025
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	24 (M)
Shares Float	21 (M)
Held by Insiders	11.3 (%)
Held by Institutions	3.2 (%)
Shares Short	377 (K)
Shares Short P.Month	391 (K)

EPS	-0.29
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.5
Profit Margin	0 %
Operating Margin	-146.6 %
Return on Assets (ttm)	-17.3 %
Return on Equity (ttm)	-47.8 %
Qtrly Rev. Growth	104.5 %
Gross Profit (p.s.)	0.03
Sales Per Share	0.03
EBITDA (p.s.)	-0.21
Qtrly Earnings Growth	0 %
Operating Cash Flow	-2 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	-7.39
PEG Ratio	0
Price to Book value	4.05
Price to Sales	62.94
Price to Cash Flow	-22.13

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.